GIMDx/Improve Medical Gain China Rights to PD-L1 Quantifying Assay

GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company. GIMDx will supply raw materials to its corporate parent, Guangzhou Improve Medical Instruments, which Improve will distribute. The products include IncellDx's proprietary single cell quantification of Programmed Death Ligand 1 (PD-L1) on tumor cells and immune cell subtypes, among other tests. Improve Medical will be the first China company to offer a quantitative PD-L1 assay. Financial details of the agreement were not disclosed.